X-Chem, ALK partner on allergy drug discovery

By The Science Advisory Board staff writers

February 5, 2020 -- X-Chem announced on February 5 a new drug discovery partnership with ALK-Abelló A/S. The collaboration will focus on the discovery of small-molecule drug products to treat a broad range of allergies.

X-Chem is a privately owned biotechnology company based in Waltham, MA. It is focused on applying its next-generation DNA-Encoded library (DEX) to discover and develop small-molecule leads against high-value therapeutic targets.

ALK is a global allergy solutions company based in Hørsholm, Denmark. It provides a wide range of products and treatments for allergy sufferers and doctors.

Under the terms of the agreement, X-Chem will utilize its DEX screening platform, which takes advantage of advanced drug-like DEX library designs and proprietary informatics tools to search for novel leads for allergy targets identified by ALK. After screening with DEX, X-Chem and ALK will collaborate to jointly advance identified leads to the clinic. Together, they will leverage X-Chem's expertise in medicinal chemistry with ALK's expertise in assays, animal models, and clinical development for the treatment of allergies. ALK will have exclusive global rights to commercialize any products resulting from the collaboration.

X-Chem received payment upfront from ALK upon signing the agreement and is eligible for future research payments and milestones based on future research achievements. X-Chem is also eligible for further payments upon ALK reaching specific regulatory and sales milestones, as well as royalties on sales of products identified under the agreement.

Evotec, Bayer partner for drug discovery in women's health
Evotec and Bayer announced on January 9 the expansion of their partnership in women's health with a new five-year, multitarget collaboration with participation...
Merck announces new drug development collaboration
Merck announced on January 6 that it has entered into an exclusive worldwide research collaboration and license agreement with Taiho Pharmaceutical and...
A discovery of fungi – helping researchers identify new drugs
To address the need to identify new therapeutic targets, researchers at the Hubrecht Institute turned to fungi. The researchers tested secondary metabolites...

Copyright © 2020 scienceboard.net

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter